Media coverage about Syndax Pharmaceuticals (NASDAQ:SNDX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave media headlines about the company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.
Several analysts have issued reports on SNDX shares. Cowen and Company restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Tuesday, May 9th. Morgan Stanley reiterated an “overweight” rating and set a $25.00 price target (up from $24.00) on shares of Syndax Pharmaceuticals in a report on Monday, July 10th. Zacks Investment Research cut Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. Oppenheimer Holdings, Inc. set a $25.00 price target on Syndax Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 18th. Finally, ValuEngine upgraded Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, May 18th. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $24.63.
Syndax Pharmaceuticals (NASDAQ SNDX) opened at 12.78 on Friday. The company’s 50-day moving average price is $12.98 and its 200-day moving average price is $11.39. Syndax Pharmaceuticals has a one year low of $6.31 and a one year high of $18.03. The stock’s market capitalization is $233.30 million.
Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Monday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.03. Syndax Pharmaceuticals had a negative return on equity of 52.82% and a negative net margin of 3,861.72%. The firm had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.31 million. Equities research analysts predict that Syndax Pharmaceuticals will post ($3.60) EPS for the current year.
In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $15.00, for a total transaction of $75,000.00. Following the completion of the sale, the insider now owns 5,000 shares of the company’s stock, valued at $75,000. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 24.10% of the stock is currently owned by insiders.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.